Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Nabriva Therapeutics PLC | NBRV | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.42 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.42 | 1.42 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.35 - 2.24 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.42 | USD |
Nabriva Therapeutics PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 0.00 | - | 37.51M | -57.19M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Nabriva Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NBRV Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 1.63 | 2.24 | 1.35 | 1.55 | 24,200 | -0.21 | -12.88% |
| 3 Years | 1.47 | 5.75 | 0.1516 | 0.9527979 | 993,246 | -0.05 | -3.40% |
| 5 Years | 29.30 | 30.70 | 0.1516 | 6.69 | 1,702,823 | -27.88 | -95.15% |
Nabriva Therapeutics Description
| Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. |
